Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recent advances of novel fourth generation EGFR inhibitors in overcoming C797S mutation of lung cancer therapy
Li Xu, Bing Xu, Jianshe Wang, et al.
European Journal of Medicinal Chemistry (2022) Vol. 245, pp. 114900-114900
Closed Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

Lazertinib: Breaking the mold of third-generation EGFR inhibitors
Kishan B. Patel, David E. Heppner
RSC Medicinal Chemistry (2025)
Open Access | Times Cited: 1
Metal/covalent-organic framework-based biosensors for nucleic acid detection
Zi-Wei Yang, Jiajing Li, Yuhan Wang, et al.
Coordination Chemistry Reviews (2023) Vol. 491, pp. 215249-215249
Closed Access | Times Cited: 24
Structure–Activity Relationship Studies Based on Quinazoline Derivatives as EGFR Kinase Inhibitors (2017–Present)
Alexandru Șandor, Ioana Ionuţ, Gabriel Marc, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 4, pp. 534-534
Open Access | Times Cited: 23
Novel 4-(2-arylidenehydrazineyl)thienopyrimidine derivatives as anticancer EGFR inhibitors: Design, synthesis, biological evaluation, kinome selectivity and in silico insights
Heba A. Elsebaie, Eman A. El-Bastawissy, Kamel M. Elberembally, et al.
Bioorganic Chemistry (2023) Vol. 140, pp. 106799-106799
Closed Access | Times Cited: 23
Next-generation EGFR tyrosine kinase inhibitors to overcome C797S mutation in non-small cell lung cancer (2019–2024)
Debasis Das, Lingzhi Xie, Hong Jian
RSC Medicinal Chemistry (2024)
Closed Access | Times Cited: 8
Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development
Carla Corvaja, Antonio Passaro, Ilaria Attili, et al.
Cancer Treatment Reviews (2024) Vol. 130, pp. 102824-102824
Closed Access | Times Cited: 6
Design, Synthesis and Evaluation of Novel Cyclopropanesulfonamide Derivatives for the Treatment of EGFRC797S Mutation in Non-Small Cell Lung Cancer
Mengxuan Wang, Zhenhong Xia, Wenyan Nie, et al.
Drug Design Development and Therapy (2025) Vol. Volume 19, pp. 1403-1420
Open Access
Design, synthesis, and biological evaluation of novel aminopyrimidine derivatives as EGFR inhibitors
Huabing Wang, Yaoting Gui, Shengkai Cui, et al.
Bioorganic & Medicinal Chemistry Letters (2025), pp. 130188-130188
Closed Access
Modeling and Interpretability Study of the Structure–Activity Relationship for Multigeneration EGFR Inhibitors
Zhiqi Sun, Donghui Huo, Jiangyu Guo, et al.
ACS Omega (2025)
Open Access
Unravelling key signaling pathways for the therapeutic targeting of non-small cell lung cancer
P. Chavan, Ruchi Pandey, BHEEMANAGOUDA O. PATIL, et al.
European Journal of Pharmacology (2025), pp. 177494-177494
Closed Access
Design, synthesis, and antitumor activity evaluation of potent fourth-generation EGFR inhibitors for treatment of Osimertinib resistant non-small cell lung cancer (NSCLC)
Yuchen Zhang, Lexian Tong, Fangjie Yan, et al.
Bioorganic Chemistry (2024) Vol. 147, pp. 107394-107394
Closed Access | Times Cited: 4
CRISPR/Cas13a-based supersensitive circulating tumor DNA assay for detecting EGFR mutations in plasma
L X Wang, Xiaosha Wen, Yang Yang, et al.
Communications Biology (2024) Vol. 7, Iss. 1
Open Access | Times Cited: 4
Novel EGFR Inhibitors against Resistant L858R/T790M/C797S Mutant for Intervention of Non-Small Cell Lung Cancer
Xiaoxue Wang, Zhongxiang Qin, W Qiu, et al.
European Journal of Medicinal Chemistry (2024) Vol. 277, pp. 116711-116711
Closed Access | Times Cited: 3
A patent review of selective CDK9 inhibitors in treating cancer
Tizhi Wu, Xiaowei Wu, Yifan Xu, et al.
Expert Opinion on Therapeutic Patents (2023) Vol. 33, Iss. 4, pp. 309-322
Closed Access | Times Cited: 9
Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies
Parth Malik, Ruma Rani, Raghu Solanki, et al.
Exploration of Targeted Anti-tumor Therapy (2023), pp. 850-895
Open Access | Times Cited: 9
Tet methylcytosine dioxygenase 2 (TET2) deficiency elicits EGFR-TKI (tyrosine kinase inhibitors) resistance in non-small cell lung cancer
Jian Zhang, Kejia Zhao, Wenjing Zhou, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 2
Discovery of Novel Fourth-Generation EGFR Inhibitors to Overcome C797S-Mediated Resistance
Yasheng Zhu, Xiuquan Ye, Hao Shen, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 21, pp. 14633-14652
Closed Access | Times Cited: 7
Cell-active, irreversible covalent inhibitors that selectively target the catalytic lysine of EGFR by using fluorosulfate-based SuFEx chemistry
Guanghui Tang, Wei Wang, Xuan Wang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 259, pp. 115671-115671
Closed Access | Times Cited: 5
Design, Synthesis, and Biological Evaluation of Novel Quinazoline Derivatives Possessing a Trifluoromethyl Moiety as Potential Antitumor Agents
M Chen, Sha Cheng, Xing Dai, et al.
Chemistry & Biodiversity (2024) Vol. 21, Iss. 5
Closed Access | Times Cited: 1
Strategies for enhancing non-small cell lung cancer treatment: Integrating Chinese herbal medicines with epidermal growth factor receptor-tyrosine kinase inhibitors therapy
Lin Chen, Wen-Da Chen, Yuxin Xu, et al.
European Journal of Pharmacology (2024) Vol. 980, pp. 176871-176871
Closed Access | Times Cited: 1
Access to 4-((Pyridin-2-yl)amino)quinazolinones via Annulation of 2-Aminobenzonitriles with N′-(Pyridin-2-yl)-N,N-dimethyl Ureas
Svetlana O. Baykova, Sergey V. Baykov, Olga V. Solodyankina, et al.
The Journal of Organic Chemistry (2024) Vol. 89, Iss. 17, pp. 12094-12103
Closed Access | Times Cited: 1
Targeted Strategies for Degradation of Key Transmembrane Proteins in Cancer
Vehary Sakanyan, Nina Iradyan, Rodolphe Alves de Sousa
BioTech (2023) Vol. 12, Iss. 3, pp. 57-57
Open Access | Times Cited: 3
Targeted Strategies for Degradation of Key Transmembrane Proteins in Cancer
Vehary Sakanyan, Nina Iradyan, Rodolphe Alves de Sousa
(2023)
Open Access | Times Cited: 2
Design and synthesis of novel EGFR kinase inhibitors for the treatment of EGFR C797S mutation in non-small cell lung cancer
Wenyan Nie, Mengxuan Wang, Zhenhong Xia, et al.
Research Square (Research Square) (2024)
Open Access
The Agonistic Activity of the Human Epidermal Growth Factor is Reduced by the D46G Substitution
Anastasia Aleksandrovna Akunevich, Vladislav Victorovich Khrustalev, Tatyana Aleksandrovna Khrustaleva, et al.
Protein and Peptide Letters (2024) Vol. 31, Iss. 7, pp. 504-518
Closed Access
Page 1 - Next Page

Scroll to top